Calidi Biotherapeutics Validates CLD-401 Manufacturing Process with FDA Feedback
Event summary
- Calidi Biotherapeutics presented its scalable manufacturing process for CLD-401 at the Bioprocessing Summit on March 12, 2026.
- FDA feedback supports the company’s approach to manufacturing CLD-401, a lead candidate from its RedTail platform.
- CLD-401 is designed to target metastatic sites and express high levels of IL-15 superagonist in the tumor microenvironment.
- Calidi anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026.
The big picture
Calidi Biotherapeutics’ presentation at the Bioprocessing Summit underscores the strategic importance of scalable manufacturing in the biotech sector, particularly for targeted genetic medicines. The FDA’s supportive feedback on CLD-401’s manufacturing process highlights the growing emphasis on regulatory alignment in the development of complex therapeutic candidates. As Calidi moves toward an IND application, its ability to secure strategic partnerships will be critical in accelerating the clinical development of its RedTail platform.
What we're watching
- Regulatory Alignment
- How FDA feedback will influence the timeline and cost of CLD-401’s clinical development.
- Manufacturing Scalability
- Whether Calidi’s proprietary manufacturing process can support commercial-scale production of CLD-401.
- Clinical Milestones
- The pace at which Calidi advances CLD-401 through IND-enabling studies and potential partnerships.
Related topics